CYSTOID MACULAR EDEMA AND MACULAR PIGMENTATION ASSOCIATED WITH NAB-PACLITAXEL THERAPY

In Brief Purpose: To report the first known case of retinal pigment epithelium hyperpigmentation changes and cystoid macular edema in a patient on nab-paclitaxel therapy. Methods: Observational case report. Results: A 72-year-old man on nab-paclitaxel therapy for non-small cell lung carcinoma developed cystoid macular edema with minimal capillary leakage with subsequent retinal pigment epithelium hyperpigmentation after resolution of cystoid macular edema. Conclusion: Nab-paclitaxel therapy may be associated with the development of retinal pigment epithelium hyperpigmentation in the setting of resolved minimal capillary leakage cystoid macular edema. Our report documents the first case of cystoid macular edema (CME) and retinal pigment epithelium (RPE) changes secondary to nab-paclitaxel use, with subsequent resolution of CME after cessation of nab-paclitaxel therapy for non-small cell carcinoma.